Phase 3 Trial Finds Daraxonrasib Doubles Median Survival to 7 Months in Advanced Pancreatic Cancer

# Phase 3 Trial Shows Daraxonrasib Doubles Median Survival in Metastatic Pancreatic Cancer Patients RevMed enrolled more than 500 patients with metastatic pancreatic ductal adenocarcinoma in a Phase 3 clinical trial for daraxonrasib. The trial involved patients whose previous treatments had failed.

Half of the participants received a daily oral dose of 300 mg daraxonrasib, while the other half were given standard-of-care intravenous chemotherapy.

Daraxonrasib successfully achieved all of the main goals laid out in the Phase 3 clinical trial. RevMed said daraxonrasib was generally well tolerated in the late-stage trial.

RevMed said daraxonrasib had a manageable safety profile in the late-stage trial. No new issues were observed with daraxonrasib in the late-stage trial. RevMed plans to submit the trial results to the FDA.

RevMed seeks approval for daraxonrasib as a second-line treatment for patients whose cancer has already spread after prior therapy. Revolution Medicines was the first cancer drug developer to receive a Commissioner’s National Priority Voucher for a cancer therapy, which places daraxonrasib's application on an expedited review track.

from Daraxonrasib Former Sen.

Ben Sasse represented Nebraska in the US Senate from 2015 to early 2023. Ben Sasse was diagnosed with Stage 4 pancreatic cancer last year. Doctors estimated Ben Sasse had three to four months to live upon diagnosis.

Ben Sasse's torso was full of tumors and the disease had spread throughout his body at diagnosis. Ben Sasse became a participant in a clinical trial for daraxonrasib. Daraxonrasib does not yet have FDA approval.

Ben Sasse is 54 years old. Ben Sasse has a wife and three children ages 24, 22, and 14. Ben Sasse told Stat News this week that daraxonrasib has reduced his tumor volume by about 60%. Ben Sasse told Stat News this week that his pain levels are way, way down.